| Names | |
|---|---|
|
IUPAC name
3-(1-Methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
|
|
| Other names
LY-317615
|
|
| Identifiers | |
|
3D model (JSmol)
|
|
| ChemSpider | |
| ECHA InfoCard | 100.233.143 |
|
PubChem CID
|
|
| UNII | |
|
|
|
|
| Properties | |
| C32H29N5O2 | |
| Molar mass | 515.62 g·mol−1 |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
|
|
|
| Infobox references | |
Enzastaurin is a synthetic bisindolylmaleimide with potential antineoplastic activity. Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply, preventing growth.
In 2013 it failed a phase III clinical trial for lymphoma.